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Background
Attention-deficit hyperactivity disorder (ADHD) is a common
neurodevelopmental disorder characterised by inattention and
hyperactivity-impulsivity that can affect people throughout their
life course. A social gradient exists in the prevalence of ADHD
in the UK. Studies in other countries have shown that social
gradients also exist in the receipt of medication for ADHD.
Socioeconomic position is potentially an unrecognised and
modifiable factor in children and young people’s receipt of
medication for ADHD in the UK.
Aim
The aim of the studywas to investigate if socioeconomic position
could explain in part whether or not children and young people in
Sheffield are receiving medication for ADHD.
Method
We used multivariate logistic regression modelling to investigate
whether socioeconomic position could explain variation in
receipt of medication for ADHD in children and young people in a
cross-sectional study. We collected data from 1354 children and
young people with a diagnosis of ADHD across three Sheffield
centres between January and December 2016. Independent
variables were age, gender, religion, ethnicity, comorbidities,
and Index of Multiple Deprivation decile (derived from home
postcode).
Results
Our results showed a social gradient in the receipt ofmedication for
ADHD (P<0.01); an increase in one decile of the Index of Multiple
Deprivation was associated with 10% lower odds of receipt of
medication for ADHD (adjusted odds ratio 0.90, 95% CI 0.84–0.97).
Conclusion
Children and young people frommore deprived backgrounds are
more likely to receive medication for ADHD. This is the first time
that a social gradient in children and young people’s receipt of
medication for ADHD has been shown in a UK sample.
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Attention-deficit hyperactivity disorder (ADHD) is a neurodevelop-
mental disorder1 characterised by inattention and hyperactivity-
impulsivity that affects 3–5% of school-age children.2 A diagnosis
in childhood requires at least six of nine criteria (five or more in
older adolescents and adults) in each of the domains (inattention
and hyperactivity-impulsivity).3 Unrecognised and therefore
untreated ADHD symptoms can have a serious negative impact
on the lives of children and young people (CYP), including their
education, social development4,5 and family relationships, which
contribute to secondary difficulties in later life5 as symptoms often
persist into adulthood.3 These difficulties also impact on the
community around them. Mainstays of treatment are firstly
behavioural interventions (such as parent management classes)
and secondly medication.4 The causes of ADHD remain a
controversial topic6 but key ADHD traits have been shown to be
over 70% heritable in meta-analysis.7 Despite core features of
ADHD being biologically determined,8 the environment is also
important, as this frames the individual and defines how they
present and function.9 It is likely that social factors affect the
presentation of ADHD,4 contributing to the heterogeneity of
ADHD presentation.
Social gradients in ADHD
Large UK studies have demonstrated a social gradient in the
prevalence of ADHD, finding that those in a lower socioeconomic
position (SEP) were more likely to have a diagnosis of ADHD.10
Even when a social gradient is found, some contend that this is a
covariate of ADHD rather than a cause,4 although there is evidence
that the effect is causal in severe early deprivation.11 Social gradients
have also been found in CYP’s receipt of medication for ADHD.12
In a study of over 2 million CYP in Sweden, the risk of ADHD
medication was higher for those aged 10–14 years, those with
more frequent hospital contact and those taking other psychotropic
medication.13 A similar study in British Colombia found that boys
are more likely to receive methylphenidate even when controlling
for ADHD symptoms and behavioural symptoms, and that prior
treatment with methylphenidate was a strong predictor of receipt
of treatment.14 A US study found that being male, school-aged,
White, living in a rural area, and being in foster care increased the
likelihood of being treated with psychotropic drugs.15 Another
national study in Sweden found that having a lone parent, receipt
of social welfare and a lower level of maternal education were asso-
ciated with taking medication for ADHD.12 Although several
studies worldwide have identified predictors of receiving medica-
tion for ADHD, no such research has yet been carried out in the
UK. This is an important gap in knowledge, as identification and
quantification of a social gradient in the receipt of medication for
ADHD in CYP in the UK could make the case for other supportive
options to modify this risk factor and improve outcomes in CYP
with ADHD. It would provide a rationale for further research into
why such a social gradient existed and how it could be alleviated.
The objective of our project was to investigate if SEP could
explain in part whether or not CYP in Sheffield are receiving
medication for ADHD.
BJPsych Open (2020)
6, e14, 1–6. doi: 10.1192/bjo.2019.87
1
Method
Study design and setting
The study was based on a cross-sectional sample of all CYP with a
recorded diagnosis of ADHDwho were seen in three secondary care
centres in Sheffield between January and December 2016. Two
centres are part of Child and Adolescent Mental Health Services
and one is based in a child development centre (Ryegate
Children’s Centre). All three offer specialist assessment for
ADHD. The three centres’ case-load includes the majority of CYP
with moderate-severe ADHD in Sheffield and the geographical
areas included have wide variation in SEP. Sheffield is an ethnically
diverse city in South Yorkshire with over 550 000 inhabitants; 36%
of Sheffield households include CYP.16
Ethical approval was granted by the Research Ethics Committee
of the School of Health and Related Research, University of
Sheffield.
Data collection and variables
We collected data on CYP’s demographics (age, gender, religion,
ethnicity, postcode), comorbid conditions and medication status.
Medication status was defined as whether or not CYPwere receiving
stimulant medication (methylphenidate or dexamphetamine in
either immediate or modified-release preparations) or atomoxetine.
Comorbidities were classified into autism spectrum disorder (ASD),
general or specific intellectual disabilities (also known as learning
difficulties in UK health services), or other. ASD and intellectual
disabilities were chosen as classifications as these were the two
most frequent recorded comorbidities in our sample.
The data were extracted from electronic patient records and
clinic letters. We used the Index of Multiple Deprivation (IMD)
as a measure of CYP’s SEP. The IMD is the official measure of rela-
tive deprivation for English lower-level super output layers (areas
the size of neighbourhoods); it is a weighted aggregate of data on
seven domains of deprivation and ranks neighbourhoods into
deciles (the first decile being the most deprived 10% of neighbour-
hoods).17 We used the Department for Communities and Local
Government’s Open Data Communities postcode lookup service
to map to each CYP’s home postcode to their IMD decile.18
The primary outcome for our analysis was medication status.
The main exposure variable was IMD decile. Age, gender, religion,
ethnicity and comorbidities were considered as potential
confounders.
Statistical analysis
Analyses were carried out in Stata/IC version 13. Data were pre-
sented as mean with standard deviation, or median with interquar-
tile range (IQR), or count with percentage. To detect significant
differences between CYP by medication status, numerical data
were compared using the Student t-test or Mann–Whitney U-test
depending on the degree of skewness in the data; categorical data
were compared using the χ2-test.
To evaluate the association between IMD and receipt of medi-
cation for ADHD, we used a multivariable logistic regression
model controlling for age, gender, ethnicity, religion, ADHD treat-
ment centre and comorbid conditions. The strength and direction of
associations were presented using adjusted odds ratios (aORs) with
95% CIs. Multicollinearity among the independent variables was
ruled out by examining Spearman’s correlations and variance infla-
tion factors. Linearity in the log(odds) for continuous variables (age
and IMD), as required by logistic regression, was assessed using
restricted cubic splines. We plotted aORs of ADHD medication
against the IMD ranks and deciles.
The multivariable logistic regression model was validated by
examining its discriminatory and calibration abilities. Calibration
(agreement between observed and predicted probabilities of receiv-
ing medication for ADHD) was assessed by the Hosmer–Lemeshow
goodness-of-fit test and by evaluating how much the slope of the
calibration line (plotting the predicted against the observed prob-
abilities) deviates from the ideal of 1.0. Discrimination ability (the
degree that the model distinguishes CYP receiving medication
from those not receiving medication) was assessed using the area
under the receiver operating characteristic curve (c-statistic).
Internal validation was performed using the bootstrap method to
calculate the c-statistic with correction for ‘optimism’ overfitting
based on 200 resamplings. An optimism-corrected c-statistic is
reduced by the estimated deterioration that the model is expected
to have when applied to new individuals.
Overall, 157/1354 CYP (11.6%) had at least one missing value in
any of study variables. ADHD medication status had 113/1354
missing values (8.3%) and IMD had 20/1354 (1.5%). Covariates
with missing values included gender (8/1354; 0.6%) and comorbid
condition (73/1354; 5.4%). The multivariable logistic regression
analysis was performed on a complete case (listwise) basis and
the ADHD centre was included in the model as a covariate to
reduce potential bias. Potential impact from missing values on the
outcome was assessed by performing sensitivity analyses in the two
extreme scenarios that: (a) all missing values in medication status
were set to ‘medicated’, and (b) all missing values in medication
status were set to ‘not medicated’. No imputation was performed
on missing covariate values.
Results
The study sample comprised 1354 CYP diagnosed with ADHD,
with a mean age of 13.6 years (s.d. = 3.1, range 5–22 years) and
1113 (82.7%) were males. CYP in the study had a median of 1
comorbid condition (IQR 0–2), including ASD (287 CYP; 22.4%),
intellectual disabilities (134 CYP; 10.5%) and ‘other’ comorbidities
(509 CYP; 39.7%). Some comorbid conditions, for example
oppositional defiant disorder, conduct disorder and developmental
coordination disorder were not possible to ascertain fully using our
data-collection method and it is likely that their prevalence is sig-
nificantly higher than figures suggested. Most CYP were of White
British ethnic origin (1080; 79.8%), and declared a Christian orien-
tation (527; 38.9%) or ‘no religion’ (662; 48.9%). The median IMD
rank was 4.7 (IQR 1.4–15.7; range 0.05–32.82) thousand units,
corresponding to a median IMD decile of 2 (IQR 1–5; range 1–10).
Information onmedication status was available for 1241 (91.7%)
CYP, of whom 1135 were prescribed ADHD medication (91.5%,
95% CI 89.8–92.9%). Table 1 shows the characteristics of the CYP
by medication status. Those CYP receiving medication for ADHD
were older (mean 13.7 v. 13.0 years, P = 0.016), more likely to have
ASD (23.2% v. 14.9%, P = 0.055) and hadmore comorbid conditions
(median 1.0 v. 0.0, P = 0.019) compared with those who did not
receive medication for ADHD. The median IMD ranks and deciles
were significantly lower in CYP receiving medication for ADHD
compared with those not receiving medication (ranks: 4.3 v. 8.1
thousands, P = 0.017; deciles: 2.0 v. 3.0, P = 0.021). No significant
differences were observed in the distributions of gender, ADHD
care centre, ethnic group or religion by medication status.
A linear relationship with the log odds of receiving ADHD
medication was found to be a good approximation for IMD ranks
or deciles, but a non-linear relationship was noted for age, which
was modelled using a restricted cubic spline with knots at quartiles
(11.3, 13.6 and 16 years) (supplementary Fig. 1 available at https://
doi.org/10.1192/bjo.2019.87). Multivariable logistic regression
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confirmed that the CYP’s receipt of medication for ADHD was sig-
nificantly and independently associated with age, comorbid ASD
and IMD decile (Table 2). In particular, an increase in every one
decile of IMD (i.e. less deprivation) was associated with a decrease
in the odds of receiving ADHD medication by 10% (aOR = 0.90,
95% CI 0.84–0.97) as shown in Fig. 1. The model’s discriminative
ability was adequate (c-statistic 0.66, 95% CI 0.60–0.72) and internal
validation indicated a small degree of overfitting (bootstrap opti-
mism-corrected c-statistic, 0.63). Model predicted probabilities
ranged between 55.2% and 98.5%. The Hosmer–Lemeshow test
(P = 0.370) and the calibration slope (0.91, 95% CI 0.50–1.32) indi-
cated good agreement between predicted and observed probabilities
of receiving medication for ADHD. In addition, the calibration
plot did not indicate a pattern of either over- or underestimation
(supplementary Fig. 2).
Sensitivity analysis accounting for potential bias from missing
values in medication status produced identical results (supplemen-
tary Table 1). The aORs of receiving ADHD medication in relation
to IMD decile were: 0.90 (95% CI, 0.85–0.97; P = 0.004) assuming
CYP with missing data were receiving medication for ADHD, and
0.94 (95% CI, 0.89–0.99; P = 0.024) assuming those CYP with
missing data were not receiving medication for ADHD.
Discussion
Our results showed a social gradient in the receipt of medication fol-
lowing a diagnosis of ADHD.CYP from amore deprived background
weremore likely to be receivingmedication for their ADHD, control-
ling for age, gender, ethnicity, religion and comorbid disorders.
CYP’s receipt of medication for ADHD was significantly and
independently associated with increasing age and comorbid ASD.
Interpretation
Our data showed that an increase in one decile of IMD (i.e. less depriv-
ation)was associatedwith 10% lower odds of receipt ofmedication for
ADHD (aOR = 0.90; 95% CI, 0.84–0.97). The finding that CYP from
more deprived backgrounds are more likely to be receiving medica-
tion has been observed in similar studies in Sweden12 and
Table 1 Characteristics of patients with attention-deficit hyperactivity disorder (ADHD) in relation to their medication status
Variable
ADHD medication status
Pa
Receiving medication
(n = 1135) Not receiving medication (n = 106)
Unknown
(n = 113)
Age in years, mean (s.d.) 13.7 (3.0) 13.0 (3.3) 12.7 (3.4) 0.016
Male, n (%)b 935 (82.7) 85 (81.0) 93 (83.8) 0.643
Care centre, n (%)
Ryegate Children’s Centre 771 (67.9) 81 (76.4) 113 (100.0) 0.195
CAMHS 1 139 (12.2) 10 (9.4) 0 (0.0)
CAMHS 2 225 (19.8) 15 (14.2) 0 (0.0)
Ethnic group, n (%)
Other 172 (15.2) 22 (20.8) 14 (12.4) 0.293
White British 907 (79.9) 80 (75.5) 93 (82.3)
Not available 56 (4.9) 4 (3.8) 6 (5.3)
Religion, n (%)
No religion 549 (48.4) 52 (49.1) 61 (54.0) 0.889
Christian 453 (39.9) 42 (39.6) 32 (28.3)
Other religion 51 (4.5) 6 (5.7) 11 (9.7)
Not available 82 (7.2) 6 (5.7) 9 (8.0)
Comorbid conditionsb
Median number (IQR) 1.0 (0.0–2.0) 0.0 (0.0–1.0) 1.0 (0.0–2.0) 0.019
Autism spectrum disorder, n (%) 257 (23.2) 15 (14.9) 15 (20.8) 0.055
Intellectual difficulties, n (%) 115 (10.4) 7 (6.9) 12 (16.7) 0.271
Other comorbidity, n (%) 445 (40.2) 35 (34.7) 29 (40.3) 0.279
Index of multiple deprivation
Rank × 1000, median (IQR) 4.3 (1.4–14.8) 8.1 (1.7–20.7) 3.7 (1.4–15.7) 0.017
Decile, median (IQR) 2.0 (1.0–5.0) 3.0 (1.0–7.0) 2.0 (1.0–5.0) 0.021
CAMHS, Child and Adolescent Mental Health Services; IQR, interquartile range.
a. Comparing those receiving medication with those not receiving medication (complete case analysis).
b. Percentages were calculated based on the number of individuals with known information. There were 8 missing values for gender and 73 missing values for comorbid condition.
Table 2 Multivariable logistic regression model for the association
between receipt of medication for attention-deficit hyperactivity disorder
and the IndexofMultipleDeprivation, controlling for patient’s age, gender,
care centre, ethnic group, religion and comorbid conditions (n = 1197)
Variable Effect measure P
IMD decile, per decile increase, aOR (95% CI) 0.90 (0.84–0.97) 0.003
Age, per year increase, aOR (95% CI)
Age spline 1 1.19 (1.04–1.36) 0.012
Age spline 2 0.85 (0.72–1.01) 0.066
Female gender, aOR (95% CI) 0.85 (0.50–1.44) 0.537
Care centre, aOR (95% CI)
Ryegate Children’s Centre 1.00 −
CAMHS 1 1.61 (0.77–3.37) 0.208
CAMHS 2 1.63 (0.89–3.00) 0.115
Ethnic group, aOR (95% CI)
Other 1.00 −
White British 1.77 (0.98–3.20) 0.057
Not stated 2.04 (0.38–10.83) 0.405
Religion, aOR (95% CI)
No religion 1.00
Christian 1.00 (0.63–1.58) 0.999
Other religion 1.19 (0.42–3.35) 0.738
Not stated 2.00 (0.49–8.07) 0.332
Comorbid conditions, aOR (95% CI)
Autism spectrum disorder 1.79 (1.00–3.18) 0.050
Intellectual difficulties 1.33 (0.59 – 3.00) 0.494
Other comorbidity 1.41 (0.90–2.21) 0.139
Model performance statistics
Calibration slope (95% CI) 0.91 (0.50–1.32)
HL goodness-of-fit, χ2 (d.f.) 8.68 (8) 0.370
C-statistic (95% CI) 0.66 (0.60–0.72)
C-statistic, BOC 0.63
IMD, Index of Multiple Deprivation; aOR, adjusted odds ratio; CAMHS, Child and
Adolescent Mental Health Services; HL, Hosmer–Lemeshow; d.f., degrees of freedom;
BOC, bootstrap optimism corrected. Age was modelled using restricted cubic splines
with slopes defined at quartiles (11.3, 13.6 and 16.0 years).
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Denmark,19 but has not been demonstrated in the UK before. It is
unlikely that the relationship between SEP and receipt of medication
for ADHD is monofactorial; and to posit that would probably be a
gross oversimplification of a complex (and possibly bi-directional)
relationship with many interacting factors, one of which we have
shown is comorbid ASD. However, the existence of a social gradient
in CYP’s medication status is important because ADHD is a
common disorder that can lead to serious negative outcomes for CYP.
Mechanisms of the social gradient
It is known that social setting influences the presentation of
childhood/adolescent ADHD4 and that deprivation makes it more
likely that CYP are exposed to a negative family, school and commu-
nity environment known to worsen ADHD presentation.20
Secondary analysis of the Millennium Cohort Study data found
that family dynamics mediated the relationship between SEP and
ADHD symptoms,21 and it may also be the case that the same
applies to receipt of medication for ADHD. In this study we do not
have a measure of severity of ADHD. The social gradient in receipt
of medication for ADHD could be because CYP from deprived back-
grounds present with more severe impairment and so are more likely
to be receiving medication. It is possible to postulate many reasons
for this. Families living in more deprived circumstances may be
less likely or even less able to seek help for possible ADHD. If they
do seek help, professionals, including teachers (who often instigate
referrals for possible ADHD) and general practitioners, may be
more likely to attribute the reported difficulties to social circum-
stances and poor parenting rather than ADHD.
It is important to consider which CYP are referred for secondary
assessment of possible ADHD in Sheffield and therefore constitute
our sample – a specialist referral is indicated if moderate/severe
impairment is thought to be present. Although it is hoped that
CYP with significant mental health comorbidity will be referred
to Child and Adolescent Mental Health Services, and those with
other neurodevelopmental difficulties to the child development
centre, the nature of ADHD is such that CYP often have additional
difficulties in both areas, thus all three centres see individuals with
complex cases. We did not identify differences in whether CYP with
ADHDwere receiving medication between centres of care, however,
it is possible that there are some differences in practices because of
the individual clinicians working in each team.
Access to services has also been shown to be a barrier to ADHD
parenting group attendance, along with dislike of group activities,
preconceptions of parenting programmes, inability to engage with
the programme (lack of understanding or finding the programme
unhelpful), or changes in circumstances.22 Each of these factors
are more likely in a deprived household where carers are likely to
have lower educational achievement or additional work and
family stressors. Not being able to benefit from first-line therapy
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Fig. 1 Adjusted odds ratios (diamonds in upper panel; solid lines in lower panel) with 95% confidence interval (capped spikes in upper panel;
dashed lined in lower panel) for the relation of the Index of Multiple Deprivation and receipt of medication in children and young adults with
Attention Deficit Hyper Activity Disorder (ADHD).
Odds ratios were estimated using logistic regression adjusting for age, sex, ethnicity, religion, care centre and comorbid conditions (n = 1197).
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for ADHD (such as parent management classes and other non-
pharmacological treatments) will lead to an increased chance of
receiving pharmacological treatment as a second-line therapy. It is
also likely that families in poorer socioeconomic circumstances do
not have the finances needed to offer their CYP’s additional
support that can reduce impairment from ADHD and therefore
the need for medication, such as sporting activities, additional
educational support and more individual adult support.
ADHD may affect SEP
It is also possible that ADHD has a part to play in determining an
individual’s SEP, which could explain in part why those with a
lower SEP are more likely to be receiving medication. It is well-
known that unrecognised and therefore untreated ADHD leads to
a range of negative outcomes including poor educational attain-
ment, fewer occupational opportunities, alcohol and substance
misuse, contact with the criminal justice system, and poor mental
health.5 Thus, adults with ADHD are more likely to live in deprived
circumstances. As ADHD traits are highly heritable,7 this effect may
have been compounded over many generations, which would lead
to more severe impairment from ADHD, and therefore leading to
CYP in such a position being more likely to be receiving medication.
One previous study did not find any evidence that families with CYP
with ADHDweremore likely tomove to a lower SEP;21 although the
study was only over a period of 7 years and may not have run for
long enough to detect changes in SEP.
Secondary findings
The clinical significance of our secondary finding that CYP with
comorbid ASD are more likely to receive medication for ADHD
is unclear. This subgroup may also be more likely to be receiving
medication as they have a higher level of impairment,23 and
should be considered at particular risk of negative outcomes
because of multiple layers of vulnerability.
The simplest explanation of our finding that CYP who are older
are more likely to be receiving medication is that the 2008 National
Institute for Health and Care Excellence (NICE) guidance recom-
mended medication as the second-line treatment for all but the
most severe ADHD and that conservative measures should be
tried first.4 The review of NICE guidance in March 2018 recom-
mends medication first line for those with moderate and severe
ADHD so this finding may change over time.24
Limitations
A key limitation in this study is the cross-sectional design – a lack of
temporality makes it difficult to infer that SEP is a causal factor of
ADHD medication status from our study alone. Severity of ADHD
was not recorded and should be included in future work; similarly,
educational attainment may be relevant for further work. Our mea-
sures of ethnicity could have been more discriminate, which would
be important to consider in further work as ethnicity has been
shown to be a predictor of whether children are receivingmedication.
Our study cannot investigate furtherwhy such a social gradient exists,
which is important to consider when evaluating whether SEP is a
modifiable risk factor. More population-based data collection over
time is needed. Although our cohort contained a large proportion
of CYP with ADHD in Sheffield, it is possible that there was some
selection bias in the cohort that cannot be accounted for in the study.
Generalisability
Sheffield is a diverse city in terms of ethnicity, income and religion;
our sample was a large cross section across these demographic facets,
with our study cohort making up a substantial proportion of all CYP
with ADHD in Sheffield. These factors make it likely that the
findings of this study are generalisable to other cities in the UK.
Implications for practice
The social gradient in CYP’s receipt of medication represents a
novel risk factor that clinicians should aim to modify. Because a
social gradient in the receipt of medication for ADHD exists,
those from more deprived backgrounds should be considered espe-
cially vulnerable regardless of causality, with clinicians thinking of
social deprivation in the same way as an additional comorbidity.
Targeted interventions for those from a lower SEP may be effective,
but progress may be difficult unless the wider inequality in our
society is addressed. Further research into why the social gradient
in CYP’s receipt of medication exists would be helpful to determine
if interventions are appropriate; and studies of the long-term effects
of increased medication use may also aid service development.
This social gradient presents a challenge not only to clinicians
but even more to politicians, public health professionals and
social care, and adds further weight to the argument that tackling
the social determinants of health should be a priority for public
health professionals and policymakers alike.
In conclusion, a social gradient is evident in the prevalence of
ADHD and in CYP’s receipt of medication in the UK. To the best
of our knowledge, this is the first study that has shown a social
gradient in ADHD drug treatment outcomes in a UK population.
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